| 2026-08-06 | Press release | Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium |
| 2026-08-04 | Deck | Earnings presentation · Q2 2026 · Aug 2026 |
| 2026-08-04 | Press release | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Re |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-21 | Press release | Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 |
| 2026-07-16 | Press release | Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and An |
| 2026-07-16 | 8-K | Form 8-K, Item 2.02 results |
| 2026-06-11 | Press release | Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting |
| 2026-05-27 | Press release | Harmony Biosciences to Participate in Upcoming Investor Conferences |
| 2026-05-14 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-07 | Deck | Q1 2026 Financial Results and Business Update |
| 2026-05-07 | Deck | Corporate Presentation · Q1 2026 |
| 2026-05-07 | Press release | Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-23 | Press release | Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-16 | Press release | Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting |
| 2026-04-14 | Press release | Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES |
| 2026-04-14 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-03 | Proxy | Definitive proxy statement |
| 2026-04-02 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-31 | Press release | Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference |
| 2026-03-04 | Press release | Harmony Biosciences to Participate in Upcoming Investor Conferences |
| 2026-02-25 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-24 | Deck | Q4 & FY 2025 Financial Results & Business Update |
| 2026-02-24 | Press release | Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion |
| 2026-02-24 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-24 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-17 | Press release | Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy |
| 2026-02-10 | Press release | Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on |
| 2026-01-13 | Deck | 44th Annual J.P. Morgan Healthcare Conference |
| 2026-01-13 | Press release | Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Poten |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-07 | Press release | Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 2025-11-04 | Press release | Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845- $865M |
| 2025-11-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-23 | 8-K | Form 8-K, Item 2.02 results |
| 2025-09-24 | 8-K | Form 8-K, Item 7.01 |